With the deadline for hospitals to recertify their eligibility for 340B drug discounts arriving on Monday, it appears most facilities will remain qualified—at least for now.
Industry observers say the COVID-19 pandemic’s impact on hospitals’ eligibility for 340B could become
…
The only clear path to resolve the impasse over the legality of 340B contract pharmacy arrangements is for Congress to clarify the 340B law, 340B Report Publisher and CEO Ted Slafsky writes in his latest column for Omnicell.
Urging
…
Federal health officials have added New Jersey and New York to the list of states granted 340B enrollment flexibility due to Hurricane Ida.
The U.S. Health Resources and Services Administration (HRSA) posted the notice about the East Coast states’ addition
…
340B covered entities are ramping up their lobbying on Capitol Hill as Congress works toward possible enactment soon of major drug pricing reforms.
Entities are telling key members of Congress and their staffs that while they support federal action to
…
Community health centers on Tuesday split their 340B dispute resolution petition against drug manufacturers Eli Lilly, Sanofi, and AstraZeneca into two—one against Lilly alone, the other against Sanofi and AstraZeneca together—to let federal officials commence proceedings against Sanofi and AstraZeneca.
…
Federal health officials are “trying to muscle an obligation” on drug manufacturers to honor 340B contract pharmacy arrangements “that simply is not there,” United Therapeutics (UT) said Tuesday in papers filed in federal district court in Washington, D.C.
Nothing in
…
Medicare Part B reimbursement for physician-administered drugs is projected to rise from $18.7 billion in 2020 to $21.7 billion this year, and then to more than double to $46.2 billion by 2030, the Medicare Board of Trustees reported to Congress
…
Louisiana and Mississippi health care providers eligible to participate in the 340B program may enroll immediately rather than having to wait until the next quarterly registration period Oct. 1 through 15, the U.S. Health Resources and Services Administration (HRSA) announced
…
Michelle Herzog, long-time second-in-command at the U.S Health Resources and Services Administration’s Office of Pharmacy Affairs (OPA), has taken charge as OPA director on an acting basis.
A HRSA spokesperson confirmed yesterday morning that Herzog will oversee OPA temporarily now
…
Passing a federal law that trims drug industry profits on companies’ top products by between 15% and 25% would lead to about 2 fewer drugs (-0.5%) being introduced in the U.S. in the law’s first decade, 23 fewer (-5%) in
…*Sign up for news summaries and alerts from 340B Report